Serial fecal calprotectin changes in children with Crohn's disease on treatment with exclusive enteral nutrition: Associations with disease activity, treatment response, and prediction of a clinical relapse

Journal of Clinical Gastroenterology

Volumn 45, Issue 3, 2011, Pages 234-239

  Gerasimidis, Konstantinos ^a   Nikolaou, Charoula Konstantia ^a   Edwards, Christine Ann ^a   McGrogan, Paraic ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

children; enteral nutrition; fecal calprotectin; inflammatory bowel disease

Indexed keywords

ANTIBIOTIC AGENT; BIOLOGICAL MARKER; CALGRANULIN; IMMUNOMODULATING AGENT; MESALAZINE; STEROID; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ADOLESCENT; ARTICLE; CHILD; CLINICAL ARTICLE; COLON SURGERY; CONTROLLED STUDY; CROHN DISEASE; DIET THERAPY; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE EXACERBATION; ENTERIC FEEDING; EXCLUSIVE ENTERAL NUTRITION; FECES ANALYSIS; FEMALE; HUMAN; MALE; PREDICTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RELAPSE; REMISSION; SCHOOL CHILD; TREATMENT RESPONSE;

EID: 85027951519     PISSN: 01920790     EISSN: None     Source Type: Journal    
DOI: 10.1097/MCG.0b013e3181f39af5     Document Type: Article

References (26)

1. Vermeire S, Van AG, Rutgeerts P. Laboratory markers in IBD: useful, magic, or unnecessary toys? Gut. 2006;55:426-431. (Pubitemid 43268284)
2. Poullis A, Foster R, Northfield TC, et al. Review article: faecal markers in the assessment of activity in inflammatory bowel disease. Aliment Pharmacol Ther. 2002;16:675-681. (Pubitemid 34407514)
3. Tibble J, Teahon K, Thjodleifsson B, et al. A simple method for assessing intestinal inflammation in Crohn's disease. Gut. 2000;47:506-513.
4. Bunn SK, Bisset WM, Main MJ, et al. Fecal calprotectin: validation as a noninvasive measure of bowel inflammation in childhood inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2001;33:14-22. (Pubitemid 32706118)
5. Roseth AG. Determination of faecal calprotectin, a novel marker of organic gastrointestinal disorders. Dig Liver Dis. 2003;35:607-609. (Pubitemid 41110869)
6. Sipponen T, Karkkainen P, Savilahti E, et al. Correlation of faecal calprotectin and lactoferrin with an endoscopic score for Crohn's disease and histological findings. Aliment Pharmacol Ther. 2008;28:1221-1229.
7. Sipponen T, Savilahti E, Kolho KL, et al. Crohn's disease activity assessed by fecal calprotectin and lactoferrin: correlation with Crohn's disease activity index and endoscopic findings. Inflamm Bowel Dis. 2008;14:40-46. (Pubitemid 351196867)
8. D'Inca R, Dal PE, Di Leo V, et al. Can calprotectin predict relapse risk in inflammatory bowel disease? Am J Gastroenterol. 2008;103:2007-2014.
9. Walkiewicz D, Werlin SL, Fish D, et al. Fecal calprotectin is useful in predicting disease relapse in pediatric inflammatory bowel disease. Inflamm Bowel Dis. 2008;14:669-673. (Pubitemid 351742984)
10. Kolho KL, Raivio T, Lindahl H, et al. Fecal calprotectin remains high during glucocorticoid therapy in children with inflammatory bowel disease. Scand J Gastroenterol. 2006;41: 720-725. (Pubitemid 43995015)
11. Hsu K, Passey RJ, Endoh Y, et al. Regulation of S100A8 by glucocorticoids. J Immunol. 2005;174:2318-2326. (Pubitemid 40223981)
12. Berni CR, Terrin G, Borrelli O, et al. Short- and long-term therapeutic efficacy of nutritional therapy and corticosteroids in paediatric Crohn's disease. Dig Liver Dis. 2006;38:381-387. (Pubitemid 44356207)
13. Department of Health. Dietary reference values for food energy and nutrients for the United Kingdom. Report on the health and social subjects. 1991.
14. Hyams JS, Ferry GD, Mandel FS, et al. Development and validation of a pediatric Crohn's disease activity index. J Pediatr Gastroenterol Nutr. 1991;12:439-447.
15. Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol. 2005;19 (suppl A):5-36.
16. Canani RB, Terrin G, Rapacciuolo L, et al. Faecal calprotectin as reliable non-invasive marker to assess the severity of mucosal inflammation in children with inflammatory bowel disease. Dig Liver Dis. 2008;40:547-553.
17. Costa F, Mumolo MG, Bellini M, et al. Role of faecal calprotectin as non-invasive marker of intestinal inflammation. Dig Liver Dis. 2003;35:642-647. (Pubitemid 41110875)
18. Fagerberg UL, Loof L, Myrdal U, et al. Colorectal inflammation is well predicted by fecal calprotectin in children with gastrointestinal symptoms. J Pediatr Gastroenterol Nutr. 2005;40:450-455. (Pubitemid 40489572)
19. Fagerberg UL, Loof L, Lindholm J, et al. Fecal calprotectin: a quantitative marker of colonic inflammation in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2007;45:414-420. (Pubitemid 350307158)
20. Konikoff MR, Denson LA. Role of fecal calprotectin as a biomarker of intestinal inflammation in inflammatory bowel disease. Inflamm Bowel Dis. 2006;12:524-534.
21. Sipponen T, Savilahti E, Karkkainen P, et al. Fecal calprotectin, lactoferrin, and endoscopic disease activity in monitoring anti-TNF-alpha therapy for Crohn's disease. Inflamm Bowel Dis. 2008;14:1392-1398.
22. Bunn SK, Bisset WM, Main MJ, et al. Fecal calprotectin as a measure of disease activity in childhood inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2001;32:171-177. (Pubitemid 32280632)
23. Borrelli O, Cordischi L, Cirulli M, et al. Polymeric diet alone versus corticosteroids in the treatment of active pediatric Crohn's disease: a randomized controlled open-label trial. Clin Gastroenterol Hepatol. 2006;4:744-753. (Pubitemid 43825808)
24. Damms A, Bischoff SC. Validation and clinical significance of a new calprotectin rapid test for the diagnosis of gastrointestinal diseases. Int J Colorectal Dis. 2008;23:985-992.
25. Vestergaard TA, Nielsen SL, Dahlerup JF, et al. Fecal calprotectin: assessment of a rapid test. Scand J Clin Lab Invest. 2008;68:343-347. (Pubitemid 351962410)
26. Day AS, Whitten KE, Lemberg DA, et al. Exclusive enteral feeding as primary therapy for Crohn's disease in Australian children and adolescents: a feasible and effective approach. J Gastroenterol Hepatol. 2006;21:1609-1614. (Pubitemid 44266523)